The second nationwide surveillance of the antimicrobial susceptibility of Neisseria gonorrhoeae from male urethritis in Japan, 2012-2013.
Worldwide, the most important concern in the treatment of sexually transmitted infections is the increase in antimicrobial resistant Neisseria gonorrhoeae strains including resistance to cephalosporins, penicillins, fluoroquinolones or macrolides. To investigate the trends of antimicrobial susceptibility among N. gonorrhoeae strains isolated from male patients with urethritis, a Japanese surveillance committee conducted the second nationwide surveillance study. Urethral discharge was collected from male patients with urethritis at 26 medical facilities from March 2012 to January 2013. Of the 151 specimens, 103 N. gonorrhoeae strains were tested for susceptibility to 20 antimicrobial agents. None of the strains was resistant to ceftriaxone, but the minimum inhibitory concentration (MIC) 90% of ceftriaxone increased to 0.125 μg/ml, and 11 (10.7%) strains were considered less susceptible with an MIC of 0.125 μg/ml. There were 11 strains resistant to cefixime, and the MICs of these strains were 0.5 μg/ml. The distributions of the MICs of fluoroquinolones, such as ciprofloxacin, levofloxacin and tosufloxacin, were bimodal. Sitafloxacin, a fluoroquinolone, showed strong activity against all strains, including strains resistant to other three fluoroquinolones, such as ciprofloxacin, levofloxacin and tosufloxacin. The azithromycin MICs in 2 strains were 1 μg/ml.
The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan. Electronic address: hamaryo@med.uoeh-u.ac.jp.
Ryoichi
R
Hamasuna
The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Gifu University Hospital, Gifu, Japan.
Mitsuru
M
Yasuda
The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, School of Medicine, Fujita Health University, Toyoake, Japan.
Kiyohito
K
Ishikawa
The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Shinya
S
Uehara
The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Blood Purification Center, Kagoshima University Hospital, Kagoshima, Japan.
Hiroshi
H
Hayami
The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Satoshi
S
Takahashi
The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Tetsuro
T
Matsumoto
The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Hyogo College of Medicine, Nishinomiya, Japan.
Shingo
S
Yamamoto
The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
Shinichi
S
Minamitani
The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
Akira
A
Watanabe
The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
Satoshi
S
Iwata
The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
Mitsuo
M
Kaku
The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
Junichi
J
Kadota
The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
Keisuke
K
Sunakawa
The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
Junko
J
Sato
Research Center for Anti-infectious Drugs, Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan.
Hideaki
H
Hanaki
Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Taiji
T
Tsukamoto
Department of Urology, The Jikei University Katsushika Medical Center, Tokyo, Japan.
Hiroshi
H
Kiyota
Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Shin
S
Egawa
Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Kazushi
K
Tanaka
Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Soichi
S
Arakawa
Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Masato
M
Fujisawa
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Hiromi
H
Kumon
Department of Urology, Institute of Biomedical & Health Sciences Hiroshima University, Hiroshima, Japan.
Kanao
K
Kobayashi
Department of Urology, Institute of Biomedical & Health Sciences Hiroshima University, Hiroshima, Japan.
Akio
A
Matsubara
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Seiji
S
Naito
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kentaro
K
Kuroiwa
Hirayama Urology Clinic, Kumamoto, Japan.
Hideo
H
Hirayama
Narita Clinic, Nagoya, Japan.
Harunori
H
Narita
Hosobe Clinic, Tokyo, Japan.
Takahide
T
Hosobe
iClinic, Sendai, Japan.
Shin
S
Ito
Ito Urology Clinic, Kitakyushu, Japan.
Kenji
K
Ito
Kawai Urology Clinic, Kitakyushu, Japan.
Shuichi
S
Kawai
Gifu Urological Clinic, Gifu, Japan.
Masayasu
M
Ito
Chokyu Tenma Clinic, Himeji, Japan.
Hirofumi
H
Chokyu
Matsumura Urology Clinic, Kato, Japan.
Masaru
M
Matsumura
Yoshioka Urology Clinic, Nishinomiya, Japan.
Masaru
M
Yoshioka
Hirajima Clinic, Okayama, Japan.
Satoshi
S
Uno
Araki Urological Clinic, Kurashiki, Japan.
Koichi
K
Monden
Department of Urology, Takayama Hospital, Chikushino, Japan.
Kazuo
K
Takayama
Kaji Clinic, Fukuoka, Japan.
Shinichi
S
Kaji
Kawahara Urology Clinic, Kagoshima, Japan.
Motoshi
M
Kawahara
Sumii Clinic, Hiroshima, Japan.
Toru
T
Sumii
Kadena Urological Clinic, Hiroshima, Japan.
Hitoshi
H
Kadena
Yamaguchi Dermatology and Urology Clinic, Munakata, Japan.
Takamasa
T
Yamaguchi
Department of Urology, Toyota Memorial Hospital, Toyota, Japan.
Shinichi
S
Maeda
Nishi Urology and Dermatology Clinic, Kitakyushu, Japan.
Shohei
S
Nishi
Nishimura Urology Clinic, Kitakyushu, Japan.
Hirofumi
H
Nishimura
Shirane Urology Clinic, Aki-gun, Japan.
Takeshi
T
Shirane
Yoh Urology and Dermatology Clinic, Inazawa, Japan.
Mutsumasa
M
Yoh
Akiyama Urology Clinic, Nishinomiya, Japan.
Kikuo
K
Akiyama
Imai Urology Clinic, Akashi, Japan.
Toshio
T
Imai
Department of Urology, Kano Hospital, Kasuya-gun, Japan.
Motonori
M
Kano
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017963:Azithromycin / Q000494:pharmacology; D020682:Cefixime / Q000494:pharmacology; D002443:Ceftriaxone / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones / Q000494:pharmacology; D006801:Humans; D007564:Japan; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009344:Neisseria gonorrhoeae / Q000187:drug effects*; D010406:Penicillins / Q000494:pharmacology; D011159:Population Surveillance; D014526:Urethritis / Q000382:microbiology*; D055815:Young Adult
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D010406:Penicillins; D002443:Ceftriaxone; D017963:Azithromycin; D020682:Cefixime
2012; 2013; Antimicrobial susceptibilities; Japan; Nationwide surveillance; Neisseria gonorrhoeae